Bcr-Abl is the cause of Philadelphia-positive (Ph þ ) leukemias and also constitutes their principal therapeutic target, as exemplified by dramatic effects of imatinib mesylate. However, mono-targeting of Bcr-Abl does not always achieve complete leukemia eradication, and additional strategies those enable complete elimination of leukemic cells are desired to develop. Here we demonstrate that INNO-406, a much more active Bcr-Abl tyrosine kinase inhibitor than imatinib, augments the activities of several proapoptotic Bcl-2 homology (BH)3-only proteins (Bim, Bad, Bmf and Bik) and induces apoptosis in Ph þ leukemia cells via Bcl-2 family-regulated intrinsic apoptosis pathway. ABT-737, an inhibitor of antiapoptotic Bcl-2 and Bcl-X L , greatly enhanced the apoptosis by INNO-406, even in INNO-406-less sensitive cells with Bcr-Abl point mutations except T315I mutation. In contrast, co-treatment with INNO-406 and other pharmacologic inducers of those BH3-only proteins, such as 17-allylaminogeldanamycin, an heat shock protein-90 inhibitor, or PS-341, a proteasome inhibitor, did not further increase the BH3-only protein levels or sensitize leukemic cells to INNO-406-induced apoptosis, suggesting a limit to how much expression levels of BH3-only proteins can be increased by anticancer agents. Thus, double-barrelled molecular targeting for Bcr-Abl-driven oncogenic signaling and the cell protection by antiapoptotic Bcl-2 family proteins may be the rational therapeutic approach for eradicating Ph þ leukemic cells.
The treatment of Philadelphia chromosome-positive (Ph þ ) leukemias has improved markedly owing to the development of inhibitors of Bcr-Abl tyrosine kinase (TK). The first member of such inhibitors is imatinib mesylate (imatinib). However, resistance to imatinib can develop by various molecular mechanisms, such as Bcr-Abl overexpression, mutations within the imatinib-binding site of Bcr-Abl, expression of a drug efflux pump or compensatory overexpression of related Src family kinases. In particular, point mutations in bcr-abl constitute the most commonly occurring and intractable. [1] [2] [3] [4] It is anticipated that these resistance mechanisms can be overcome by developing more potent Bcr-Abl inhibitors that possess higher affinity for Bcr-Abl and are active against imatinib-insensitive mutated Bcr-Abl proteins. As a result, several 'second-generation' Bcr-Abl inhibitors, including dasatinib and nilotinib, have been developed. 5, 6 We have developed INNO-406 (formerly NS-187), which blocks BcrAbl autophosphorylation in vitro 25-to 55-fold more efficiently than imatinib and is at least 10 times more effective than imatinib in suppressing the growth of Bcr-Abl-positive (BcrAbl þ ) leukemic tumors in vivo. Moreover, INNO-406 inhibits the TK activities of most of the imatinib-resistant-mutated Bcr-Abl proteins except T315I mutant. 7, 8 However, it appears that a few leukemic cells often survive exposure to imatinib or second-generation Bcr-Abl inhibitors. 9, 10 Indeed, mathematical modeling studies suggest that complete eradication of Bcr-Abl þ leukemic cells may require simultaneous targeting of other vital molecules. 11, 12 Here, we have sought to identify additional therapeutic targets by characterizing the molecular mechanism by which the blockade of Bcr-Abl signaling kills Ph þ leukemia cells. Our study reveals that INNO-406-induced cell death is regulated by the interplay of pro-and antiapoptotic Bcl-2 family proteins that share one to four 'Bcl-2 homology domains (BH1, 2, 3 and BH4)'. Of particular importance are the BH3-only proteins, which are a subgroup of proapoptotic Bcl-2 proteins that share only BH3 region and are essential for initiating apoptosis. 13, 14 As we found that several BH3-only proteins, Bim, Bad, Bmf and Bik, play essential roles in INNO-406-induced apoptosis, we assessed whether co-treatment with a drug that activates these BH3-only proteins would enhance the killing of BcrAbl þ leukemia cells by . The drugs tested included 17-allylaminogeldanamycin (17-AAG), a heat shock protein (HSP)-90 inhibitor and PS-341, a proteasome inhibitor; both have previously been shown to elevate Bim, Bad, Bmf or Bik expression. [15] [16] [17] [18] We also examined whether the killing of INNO-406 could be enhanced by co-treatment with ABT-737, a drug that decreases the antiapoptotic barrier imposed by the antiapoptotic Bcl-2 family members Bcl-2, Bcl-X L and Bcl-w. 19, 20 Our study shows that simultaneously targeting both pro-and antiapoptotic molecules augments the killing achieved with INNO-406, even in Bcr-Abl þ leukemias bearing imatinib-resistant Bcr-Abl point mutations. Notably, like Ph þ leukemias, most cancers maintain and propagate themselves by resisting apoptosis and enhancing cell proliferation. Inhibition of signaling for cell proliferation causes the cell cycle arrest as well as the initiation of apoptotic cell death. Thus, a double-barrelled therapeutic strategy like the one described here that targets both apoptosis resistance and enhanced proliferation of tumor cells may also be suitable for other cancers. To identify the apoptotic pathway that is stimulated by INNO-406, we examined the effect of INNO-406 on genetically engineered K562 subclones that overexpressed human Bcl-2 (K562/Bcl-2) or a dominant-interfering mutant of Fasassociated death domain (FADD)/MORT1 (K562/FADD-DN), which inhibits death receptor-induced apoptosis; both molecules were labeled with an N-terminal Flag tag (Figure 1c) . [21] [22] [23] We found that Bcl-2 overexpression blocked INNO-406-induced K562 cell death, whereas FADD-DN had no effect. Moreover, BV173R, a subclone of BV173, which expresses higher levels of Bcl-2 than parental BV173 cells, was less sensitive to INNO-406-induced cell death than BV173 (Figure 1c, d ). These results demonstrate that INNO-406 induces apoptosis of Bcr-Abl þ cells via the Bcl-2 family-regulated intrinsic apoptotic pathway.
Recently, Bim, a member of the proapoptotic BH3-only subgroup of the Bcl-2 family, was found to participate in imatinib-induced apoptosis of Ph þ leukemia cells. 15, 22, 24 Importantly, we found that the K562/short hairpin (sh) Bim (Figure 2c ). These findings were also the cases with bcr-abltransformed FLCs. Within 6 h, the levels and migration speed of Bim EL increased, Bad became dephosphorylated, and the levels of Bmf and to low extent also those of Bik increased (Figure 2d ). In contrast, Puma or Noxa protein was not increased, but decreased, after INNO-406 treatment (Supplementary Figure 1) . Bim and Bad, is also known to be a client of HSP-90. 27 Thus, 17-AAG may restore the Bim and Bad levels and their proapoptotic activity in bcr-abl-expressing cells. Indeed, treatment of K562 and BV173 cells with 17-AAG caused an increase in the levels of Bim, Bmf and Bik, Bad dephosphorylation and a faint reduction in the levels of antiapoptotic Mcl-1 (Figure 4b , c). 17-AAG caused a dosedependent apoptosis over 48 h that plateaued around 0.5 mM and the apoptosis by 17-AAG was partially inhibited by Bim knockdown and almost entirely blocked by Bcl-2 overexpression. Contrary to our expectation, co-treatment with 17-AAG did not augment INNO-406-induced killing of K562 or BV173 cells (Figure 5a, Supplementary Figure 2a) , and the two agents together cannot enhance the activation of these BH3-only proteins further (Figure 4b ).
Loss of

Effect of combined treatment or Bcr-Abl
þ cells with INNO-406 and PS-341. Even though PS-341 treatment did not affect Bcl-2 or Bcl-X L level, but accumulated Mcl-1 in K562 cells, it elevated caspase-8 activity (Figure 4a,c,d ). This indicates that it operates by a pathway that differs from 
or Bcr-Abl H396P , much higher concentrations are needed to kill cells expressing these mutants than are needed for killing cells containing wt Bcr-Abl. 7 Thus, we examined whether lowering of the antiapoptotic barricade by treatment with ABT-737 could restore the ability of INNO-406 to kill leukemic cells bearing imatinib-resistant Bcr-Abl. For this, we generated Ba/F3-derived murine hematopoietic cell lines transformed with wt p210-Bcr-Abl (Ba/F3/wt bcr-abl (Figure 6b ). These observations were paralleled by the effect of treatment on Bcr-Abl phosphorylation, as the wt Bcr-Abl expressing cells showed marked downregulation of Bcr-Abl phosphorylation, whereas this effect was less pronounced in cells expressing the E255K mutant and absent in those expressing the T315I mutant. As expected, INNO-406 induced much less Bim upregulation in the E255K and H396P mutant Bcr-Abl cells than in Ba/F3/wt bcr-abl cells, and had no effect on the levels or phosphorylation of Bim in Ba/F3/T315I bcr-abl cells (Figure 6a and data not shown) . When the cells were 17-AAG plus ABT-737 produces more cell killing effects even in cells expressing mutant Bcr-Abl T315I than either drug alone. Given that 17-AAG activates Bim, Bad, Bmf and Bik and slightly reduces Mcl-1 through the blockade of Bcr-Abl (Figure 4b, c) , we next examined whether cell death inducing effect by 17-AAG could be also enhanced by ABT-737. As shown in Figure 7 , the combination of these two agents produced more cell death not only in INNO-406-sensitive cells (i.e. Ba/F3/wt bcr-abl, Ba/F3/E255K and Ba/F3/H396P in this study) but also, importantly, in INNO-406-insensitive leukemic cells harboring T315I mutation. These again indicate that the inhibition of antiapoptotic Bcl-2 proteins is effective approach to augment the cell killing effect by the blockade of Bcr-Abl, and this combination could be a good alternative approach for leukemic cells insensitive to Bcr-Abl TK inhibitors.
Combination effect of INNO-406 and ABT-737 on imatinib-resistant MYL cells expressing higher level of
Mcl-1. Finally, we examined the effects of INNO-406, ABT-737 and their combination on imatinib-resistant MYL-R cells. MYL-R was generated by continuous exposure up to 1.0 mM imatinib in culture, and was found to express higher level of Mcl-1, whereas the levels of Bim or other BH3-only proteins were not reduced (unpublished data) (Supplementary Figure  3a) . 28 When compared with MYL, MYL-R was resistant to cell death either by INNO-406 or ABT-737, and the cell death by INNO-406 was increased only when the higher concentration of ABT-737 was combined ( Supplementary  Figure 3b, c) .
Discussion
Bcr-Abl is the principal molecular target against Ph þ leukemias; however, the mono-targeting of Bcr-Abl appears to be insufficient for the complete eradication. Clinically, a number of patients who achieve molecular remission upon imatinib treatment suffer disease relapse when the drug is discontinued. 29, 30 Furthermore, Bcr-Abl inhibitors have been shown to be more cytostatic than cytotoxic against Bcr-Abl þ leukemic cells. 9, 10 These suggest that the complete eradication of Bcr-Abl þ leukemic cells may require Bcr-Abl inhibitors in combination with therapies that modify the molecular pathways that control cell survival. Our study supports this premise, as we were able to markedly increase the killing of transcriptional activator of bim. 31 Loss of ERK1/2 or AKT kinase activity is probably responsible for de-phosphorylation and activation of Bim and Bad, respectively. 32 INNO-406 induces Bmf and Bik approximately 30-fold more potently than imatinib, but how this is achieved is presently unknown.
Based on these observations, we searched for promising agents whose combination with INNO-406 would enhance its apoptotic effect. We first tested two clinically available agents, 17-AAG and PS-341, both of which are able to increase the levels of Bim, Bad, Bmf and/or Bik in cancer cells. 15, 17, 18 Indeed, 17-AAG potently increased Bim, Bmf and Bik expression and caused Bad dephosphorylation in Bcr-Abl þ cells, but its combination with INNO-406 did not further increase the expression of the BH3-only proteins or enhance cell killing. A possible explanation for this could be that there is a limit to how much expression levels of BH3-only proteins can be increased. Like 17-AAG, PS-341 co-treatment with INNO-406 did not further elevate BH3-only protein levels, but it increased cell killing via a distinct pathway to that used by INNO-406. The cell death pathway activated by PS-341 is currently unclear. Although this drug triggered caspase-8 cleavage, a hallmark of the extrinsic apoptosis pathway, the K562/FADD.DN was only marginally resistant to PS-341 (data not shown). This suggests that PS-341-induced cell killing is unlikely to be mediated by the extrinsic apoptosis pathway. Instead, this drug may induce endoplasmic reticulum (ER) stress-mediated cell death via the unfolded protein response, 33 although it should be noted that the involvement of caspase-8 in ER-stress-mediated cell death remains controversial. In any case, these observations indicate that seeking to elevate the effects of INNO-406 on the expression and activation of BH3-only proteins, such as Bim or Bad, by using other BH3-only protein-stimulating agents is unlikely to be an effective strategy.
Next, we examined the effect of co-treatment with ABT-737 and INNO-406. ABT-737 dramatically augmented the killing of CML-derived cell lines by INNO-406. Moreover, co-treatment with ABT-737 was able to overcome the resistance to INNO-406-induced cell death that was caused by the abrogation of the intrinsic apoptotic pathway, caused either by Bcl-2 overexpression or Bim knockdown. Although the mechanism has not been fully elucidated, Mcl-1 might have important role in the combination of INNO-406 and ABT-737. 19, 34 This combination effect could be explained by the neutralization of Mcl-1 by Bim, which was not only induced by INNO-406 but also dissociated from Bim/Bcl-2 complex by ABT-737. 19, 34 Indeed, the combination effect was largely abrogated in Mcl-1 highly expressing MYL-R (Supplementary Figure 3a, c) . Collectively, these results suggest the involvement of Mcl-1 in determining the sensitivity for the combination therapy of INNO-406 and ABT-737.
Remarkably, ABT-737 potently sensitized cells bearing the E255K or H396P Bcr-Abl point mutations to INNO-406-induced apoptosis, such that they were killed as efficiently as INNO-406-treated cells bearing the wt Bcr-Abl protein.
Imatinib in combination with ABT-737 did not achieve this effect (unpublished data). However, ABT-737 did not sensitize cells with the T315I-bearing Bcr-Abl protein to INNO-406-induced cell death, which indicates that ABT-737 can act synergistically only when its partner agent retains at least some activity against target cells. On the basis of these results, we examined the effect of treating Bcr-Abl þ leukemias with both 17-AAG and ABT-737. We were interested in particular in the effect of this treatment regimen on leukemic cells with the T315I mutation, as 17-AAG has been shown to exert anti-Bcr-Abl þ leukemia effects regardless of the Abl point mutation status. 35 Although 17-AAG killed leukemic cells expressing wt Bcr-Abl less potently than INNO-406, its effects were markedly augmented by ABT-737; moreover, the co-treatment efficiently killed cells with the E255K, H369P and even the T315I point mutations (Figure 7) . These observations confirm that dual targeting of Bcr-Abl and antiapoptotic Bcl-2 proteins may be an effective strategy for treating Bcr-Abl þ leukemias. In addition, ABT-737 has been already demonstrated to be active against primitive leukemic stem cells (LSCs) in acute myeloid leukemias. 19 Besides sensitizing to apoptosis, ABT-737 may be also expected to eradicate Bcr-Abl þ LSCs those may escape the killing by Bcr-Abl inhibitors. 9, 10 How does the dual targeting of Bcr-Abl and antiapoptotic Bcl-2 proteins synergize in eradicating Bcr-Abl þ leukemias? To maintain and expand the tumor, leukemic cells need to maintain their capacity for cell proliferation, while being resistant to apoptosis in the face of cytotoxic or environmental insults. 36 In Ph þ leukemias, Bcr-Abl and its downstream signaling cascades promote both cell proliferation and resistance to apoptotic stimuli. The antiapoptotic Bcl-2 and Bcl-X L proteins can further increase apoptosis resistance of Bcr-Abl-transformed cells. 37 The extent to which these two distinct, but converging, molecular pathways operate in particular leukemic cells may vary depending on the cellular context. This is shown by the differences in the responses of K562 and BV173 to INNO-406 or ABT-737. Moreover, it has been reported that coexpression of Bcl-2, but not Ras or Myc, promoted the blastic transformation of myeloproliferative disease in Bcr-Abl transgenic mice. 38 This again indicates the biological significance of the acquisition of an antiapoptotic phenotype in Ph þ leukemias in addition to the oncogenic signaling by Bcr-Abl. This may help explain why blocking only the signaling cascades promoting cell proliferation does not eradicate leukemic cells, as these cells are also highly protected by an antiapoptotic molecular network (Figure 8) . Consequently, the concomitant blockade of molecules involved in the latter molecular network may help to augment the therapeutic efficacies of Bcr-Abl inhibitors.
In conclusion, the therapeutic effects of Bcr-Abl inhibitors, such as INNO-406, that strongly induces and activates BH3-only proteins can be significantly boosted by co-treatment with inhibitor, like ABT-737, that blocks antiapoptotic Bcl-2/Bcl-X L proteins.
Materials and Methods
Cell lines, generation of subclones and reagents. K562 is an erythroleukemia, BV173 is a pre-B leukemia and MYL is a myeloid leukemia cell line; all were derived from Ph þ CML patients in blast crisis phase. Long-term culture resulted in the isolation of the BV173R subclone, which is more resistant to imatinib-induced cell death than the parental BV173 cells. K562/Bcl-2 and K562/ FADD-DN were generated as described previously; both molecules were labeled with an N-terminal Flag tag, and the former inhibits the mitochondria-mediated intrinsic apoptotic pathway, whereas the latter protein inhibits death receptorinduced apoptosis. K562/shBim and BV173R BV173R/shBim cell lines were generated by using the anti-Bim shRNA construct cloned into the pSUPER vector. [21] [22] [23] 39 MYL and its imatinib-resistant subclone MYL-R were kind gifts from Dr. Hideo Tanaka (Hiroshima University, Japan). 28 We generated Ba/F3-derived murine hematopoietic cell lines transformed with wt p210-Bcr-Abl (Ba/F3/wt . ) or BcrAbl bearing the E255K (Ba/F3/E255K), T315I (Ba/F3/T315I) or the H396P mutation (Ba/F3/H396P). 7, 8 Murine FLCs that were retrovirally transformed with the bcr-abl gene were previously described, according to the guidelines of the Melbourne Directorate Animal Ethics Committee. 22 INNO-406 was provided by Nippon Shinyaku (Kyoto, Japan). Imatinib and PS-341 were purchased from a pharmacy. 17-AAG was purchased from Calbiochem (La Jolla, CA, USA). ABT-737 was produced by Dr. Michael Andreeff. 19 Low-binding pipette tips and tubes (Sorenson BioScience Inc., Salt Lake City, UT, USA) were used for handling ABT-737 throughout this study.
Quantitative RT-PCR. Total RNA was extracted by using the Micro-to-Midi Total RNA Extraction Kit (Invitrogen, San Diego, CA, USA) and subjected to reverse transcription. 40 . The mRNA levels of human bad, bik, bim, bmf, hrk, noxa and puma were analyzed by using the LightCycler System (Roche Diagnostics, Sandhoferstrabe, Mannheim, Germany) with FastStart DNA Master SYBR Green I (Roche). Amplicons were validated by their melting curve and electrophoresis. The expression levels of the target mRNAs were normalized with that of the housekeeping gene b-actin. Informations on primers used are shown in Supplementary Table.
Western blotting. Protein samples were separated by SDS-PAGE and then electroblotted onto a Hybond-PDVF membrane (Amersham Biosciences, Uppsala, Sweden). The membranes were saturated with 5% (wt/vol) non-fat dry milk in PBS with 0.1% (vol/vol) Tween 20 (Sigma, Saint Luis, MO, USA). Antibodies (Abs) against b-actin (Sigma), Bcl-2 (Bcl-2-100, Upstate, Lake Placid, NY, USA), Bcl-X L (Stressgen, Victoria, Canada), Bik (Santa Cruz Biotechnology, Santa Cruz, CA, USA), Bim (clone 3C5, produced by Dr. LA O'Reilly), Bad (Stressgen for human Bad, and Cell Signaling Technologies, Beverly, MA, USA, for murine Bad), Bmf (clone 9C10, Alexis, for human Bmf and clone 17A9 from Dr. LA O'Reilly for mouse Bmf), c-Abl (Santa Cruz), caspase-8 (BD Pharmingen, San Diego, CA, USA), FLAG (M2, Sigma), Mcl-1 (Santa Cruz), Noxa (Alexis Biochemicals, San Diego, CA, USA), phospho-Bad (Cell Signaling Technologies), phospho-tyrosine (Upstate) and Puma (ProSci Inc., Poway, CA, USA) were utilized. Ab detection was achieved by using horseradish peroxidase-conjugated secondary Abs and enhanced chemiluminescence (ECL) or ECL advance (Amersham Biosciences).
Cell death assay and DNA fragmentation assay. The incorporation of propidium iodide (PI) was used to detect dead cells in flow cytometric analysis. The DNA fragmentation assay was performed by using the Apo Ladder kit (TAKARA, Shiga, Japan).
Caspase-8 activity. Caspase-8 activity was measured by using the caspase-8 fluorometric assay kit (MBL, Nagoya, Japan) and Wallac Victor 2 Multi-label Counters (Perkin Elmer, Wellesley, MA). 
